For all press and media enquiries please contact mediarelations@chiesi.com
Agreement marks a historic partnership for respiratory care in Europe MUNICH and PARMA, November 30, 2020 - Kaia Health, a leading digital therapeutics company, and Chiesi Group, an international research-focused healthcare group, announced that they have entered into an exclusive partnership to…
The Group achieves the 10 th position (just one other Italian company is between the first 10), among the most inclusive companies in Europe and the 1 st position in the Pharmaceutical and Biotechnology sector; In Italy, Chiesi ranks 2 nd among the 35 companies qualifying for the ranking. Parma,…
Chiesi Farmaceutici, an international research-focussed pharmaceutical group, announces the launch of the website www.artedellacura.com. A cultural and historical account consisting of three virtual itineraries which set out to discover some of the places symbolising the link between Parma and the…
Chiesi Farmaceutici receives the award reserved to large Companies and recognises their outstanding contribution to gender equality and to enhancing the value of women in the workplace Parma, October 15 th, 2020 – Chiesi Farmaceutici, an international research-focussed pharmaceutical group,…
This year, all of the Group’s affiliates, employees, communities and the company’s partners will be attending a virtual edition of the event to confirm Chiesi’s commitment towards people, the community and the environment. Parma, 24 th September 2020 – Chiesi Farmaceutici, an international…
Parma, 18th September 2020 – Chiesi Farmaceutici, an international research-focussed group, announces the appointment of Dr. Alberto Chiesi, President of the Group, to Knight of the Légion d’Honneur, the highest order of merit awarded by the Republic of France. The appointment, which was established…
CAMBRIDGE, Mass. and Parma, Italy – September 16, 2020 – Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi Farmaceutici S.p.A., an international…
€1,992.81 million, around 6,000 employees, an 11% reduction in CO 2 emissions and more than a fourfold increase in renewable energy consumption – these are some of the Group’s figures; The report, which is based on the approach of renowned US economist and essayist Jeffrey Sachs, includes Chiesi’s…
GUILFORD, CONN., U.S.A. and PARMA, ITALY – BIOASIS TECHNOLOGIES INC. (“ Bioasis ”) (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 TMplatform technology for the delivery of therapeutics across the blood-brain barrier (“ BBB ”) and…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
